Current considerations of the etiology of aplastic anemia.
Aplastic anemia is a disorder characterized by marrow aplasia and pancytopenia. The pathogenetic mechanisms that lead to bone marrow aplasia have been intensively studied. Data obtained from these studies suggest that aplastic anemia is a heterogeneous disorder with regards to pathogenesis. Bone marrow aplasia may result from a number of abnormalities including qualitative or quantitative abnormalities of hematopoietic stem cells, abnormal interaction between bone marrow accessory cells (lymphocytes and macrophages) and hematopoietic stem cells, cytotoxic humoral inhibitors of hematopoiesis, and abnormalities of the bone marrow microenvironment. A number of new therapeutic options have improved the survival of patients with aplastic anemia. Allogeneic bone marrow transplantation has actually resulted in the cure of patients. Unfortunately, only a minority of patients have a suitable bone marrow donor and alternate modes of therapy have been sought. Encouraging results have been reported from several centers concerning the use of antilymphocyte serum in patients with aplastic anemia. Certainty of the ultimate long-term benefit of this type of immunosuppressive therapy is not possible until careful, randomized, prospective studies of its use are completed.
D000367:Age Factors; D000741:Anemia, Aplastic / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D001327:Autoimmune Diseases / Q000150:complications; D001853:Bone Marrow / Q000503:physiopathology; D002450:Cell Communication; D002454:Cell Differentiation; D004777:Environment; D004920:Erythropoiesis; D005786:Gene Expression Regulation; D005809:Genes, Regulator; D006410:Hematopoiesis; D006412:Hematopoietic Stem Cells / Q000503:physiopathology; D006801:Humans; D007239:Infections / Q000150:complications